bpc-157 human clinical trials back pain and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157: The Secret Weapon for

The pop-culture interest in BPC-157 reflects a real evidence base, even if that base remains pre-human-RCT in its current form

Lieberman's review of biphasic anaphylaxis estimates the biphasic rate at 1-20% of anaphylaxis cases, supporting routine corticosteroid prophylaxis after moderate-to-severe reactions

The owner of Paradigm Peptides, Matthew Kawa, was jailed for five years and 10 months on Thursday after he admitted deliberately selling unapproved medicines, trying to deceive people about what they were and illegally bringing the products into the country

doi:10.1016/j.mehy.2021.110736 [3] Veljaca M., Sladoljev D., Mildner B